Al Mayadeen English

  • Ar
  • Es
  • x
Al Mayadeen English

Slogan

  • News
    • Politics
    • Economy
    • Sports
    • Arts&Culture
    • Health
    • Miscellaneous
    • Technology
    • Environment
  • Articles
    • Opinion
    • Analysis
    • Blog
    • Features
  • Videos
    • NewsFeed
    • Video Features
    • Explainers
    • TV
    • Digital Series
  • Infographs
  • In Pictures
  • • LIVE
News
  • Politics
  • Economy
  • Sports
  • Arts&Culture
  • Health
  • Miscellaneous
  • Technology
  • Environment
Articles
  • Opinion
  • Analysis
  • Blog
  • Features
Videos
  • NewsFeed
  • Video Features
  • Explainers
  • TV
  • Digital Series
Infographs
In Pictures
  • Africa
  • Asia
  • Asia-Pacific
  • Europe
  • Latin America
  • MENA
  • Palestine
  • US & Canada
BREAKING
Al Mayadeen's correspondent: Two people martyred in the Israeli airstrike that targeted a vehicle in Toul.
Al Mayadeen's correspondent in South Lebanon: Israeli drone strikes vehicle in town of Toul, South Lebanon.
Al Mayadeen's EU delegate: Belgium categorically refused to touch Russian assets in its banks for fear of a Russian judicial backlash
Al Mayadeen's EU delegate: The European Union has failed to reach an agreement on the use of Russian assets frozen in Belgium
Trump: Will be seeing land action in Venezuela soon
Trump: first question to Xi will be fentanyl
Trump on reports of B1 bombers near Venezuela: Reports are not accurate
Al Mayadeen's correspondent: The death toll from the airstrike that targeted the town of Arabsalim in South Lebanon has risen to two, in addition to four injuries
Al Mayadeen's correspondent in South Lebanon: An Israeli airstrike targeted the town of Arabsalim
Putin on new sanctions against Russia: Russia's energy sector remains confident, though some losses are expected

New cancer treatment offers hope to patients out of options

  • By Al Mayadeen English
  • Source: Agencies
  • 22 Aug 2022 08:45
4 Min Read

Oncologists in the UK discover that combining immunotherapy with guadecitabine, a novel investigational medicine, can reverse cancer's resistance to immunotherapy.

  • x
  • New cancer treatment offers hope to patients out of options.
    New cancer treatment offers hope to patients out of options.

A newly discovered cancer treatment can stop the disease from advancing in patients who are resistant to immunotherapy. 

Immunotherapy is a type of cancer treatment that employs the immune system to target and kill cancer cells. It can save lives when other treatment choices, such as surgery, radiotherapy, or chemotherapy, have failed. Treatment cannot, however, benefit all patients, and some tumors can adapt to resist it.

Oncologists in the United Kingdom have discovered that combining immunotherapy with guadecitabine, a novel investigational medicine, can reverse cancer's resistance to immunotherapy. They discovered that patients who were anticipated to die after exhausted all therapy options lived far longer.

Read next: Almost half of cancer deaths connected to preventable factors: Study

The combination of immunotherapy medicine pembrolizumab and next-generation DNA hypomethylating agent guadecitabine slowed the progression of cancer in more than a third of patients enrolled in the early phase 1 trial. The findings were published in the Journal for ImmunoTherapy of Cancer.

The combination could become an effective weapon against different forms of cancer, experts revealed at the Institute of Cancer Research and Royal Marsden NHS foundation trust. 

Patients in the trial, from the Royal Marsden and University College London hospital, included those with lung, breast, prostate, and bowel cancer.

Treatment 

Related News

Russia to begin treating patients with AI-designed cancer vaccine

Russia completes preclinical trials of cancer vaccine, seeks approval

The study used pembrolizumab and guadecitabine to treat 34 cancer patients, 30 of whom had their tumors analyzed for immune activity and cancer growth. Every three weeks for three years, they had an injection of guadecitabine for four days in a row – and pembrolizumab on the first of those days.

Pembrolizumab is an immune checkpoint inhibitor drug that has already proved successful in treating a range of cancers, including lung and skin cancers. However, tumors can develop resistance to it and some patients who initially benefit will eventually get sicker.

Read next: AI tool accurately predicts tumor regrowth in cancer patients

The study lead, Anna Minchom, a clinical scientist at the Institute of Cancer Research and a consultant medical oncologist at the Royal Marsden, said: “Immunotherapy has shown amazing promise in cancer care over the last decade, but it doesn’t work well in all cancers and cancers can often become resistant. This combination might be a way to target their cancer even after it has stopped responding to immunotherapy.”

Guadecitabine may help overcome this resistance, doctors, researchers and scientists involved in the trial have discovered.

37% record no tumor progression 

The tumor stopped progressing in 37% of the 30 patients whose cancer activity was studied, during 24 weeks or more. Prior to the experiment, three-fifths of the cohort (60%) were resistant to immunotherapy. Almost four in ten (39%) did not become ill as a result of the drug combination.

The new treatment could help lung cancer patients. Of those resistant to immunotherapy, half had their disease controlled for 24 weeks or more.

A patient from Dorset, Alison Sowden, was diagnosed with lung cancer four years ago and was told she had a year to live, but then received pembrolizumab for three years. She is now free of cancer.

“I know there is a chance that my cancer may come back and develop resistance to treatment, so it is reassuring to know research efforts aiming to reverse cancer’s resistance to immunotherapy are under way,” she said.

“I hope this new experimental drug combination will eventually make it to the clinic and help people who have developed resistance to pembrolizumab.”

  • Cancer
  • United Kingdom

Most Read

From previous scenes of the Qassam Brigades targeting an Israeli D9 bulldozer with a Yassin 105 shell, east of Deir al-Balah. (Military Media of the Qassam Brigades)

US knew fatal Rafah blast cause was not Hamas op., says journalist

  • Politics
  • 20 Oct 2025
Abu Hamza, the spokesperson for the Al-Quds Brigades, during a speech televised on October 22, 2025 (Al-Quds Brigades Military Media)

Al-Quds Brigades' Abu Hamza mourns leaders, vows continued resistance

  • Politics
  • 22 Oct 2025
'Israel’s Digital Iron Dome: Weaponizing the web against Palestine

'Israel’s Digital Iron Dome: Weaponizing the web against Palestine

  • Technology
  • Today
US missionary kidnapped in Niger capital, suspected taken toward Mali

US missionary kidnapped in Niger capital, suspected taken toward Mali

  • Africa
  • 23 Oct 2025

Coverage

All
War on Gaza

Read Next

All
Palestinians walk through the destruction caused by the Israeli air and ground offensive in Gaza City, Thursday, October 23, 2025. (AP Photo/Abdel Kareem Hana)
Politics

Unexploded ordnances in Gaza may take 30 yrs to clear, aid group says

Police stand guard before a press conference on the extradition of “Tren de Aragua” gang members from the United States, at the a high-security prison where they are being held in Santiago, Chile, Wednesday, October 1, 2025. (AP Photo/Esteban Félix)
Politics

US immigration policies shaped by false 'Venezuela gang' threats

Demonstrators march at a protest opposing "Operation Midway Blitz" and the presence of ICE, Tuesday, Sept. 9, 2025, in Chicago (AP)
Politics

HRW slams federal agents use of excessive force in Illinois protests

Lebanese President Joseph Aoun meets with the Lebanese Prime Minister Nawwaf Salam ahead of a Cabinet meeting in the Presidential Palace, Baabda, Lebanon, October 23, 2025 (X/ @LBPresidency)
Politics

Lebanon OKs sea demarcation with Cyprus, restarts Block 8 exploration

Al Mayadeen English

Al Mayadeen is an Arab Independent Media Satellite Channel.

All Rights Reserved

  • x
  • Privacy Policy
  • About Us
  • Contact Us
  • Authors
Android
iOS